Contact Information: GLOBEIMMUNE CONTACTS: Timothy C. Rodell, M.D. President & Chief Executive Officer GlobeImmune, Inc. T: 303-625-2820 Jeffrey Rona Chief Business Officer GlobeImmune, Inc. T: 303-625-2720 C: 303-523-4014
GlobeImmune Raises $41.2 Million in Series C Financing
| Source: GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - September 26, 2007) - GlobeImmune, Inc. today announced it has
raised $41.2 million through a Series C Preferred Stock financing. This
round was led by Wexford Capital LLC, and as a result of its investment,
Paul A. Mieyal, Ph.D., has joined GlobeImmune's Board of Directors.
Other new investors to GlobeImmune included Celgene, Inc., Mellon Family
Investment Company, Richard King Mellon Foundation, Eminent Venture
Capital, Boston Life Science Venture, and WRF Capital. Previous investors
participating in the current round included HealthCare Ventures,
Morgenthaler Ventures, Sequel Venture Partners, Lilly Ventures, Medica
Venture Partners, Adams Street Partners, Biogen Idec, Inc., Pac-Link
Bioventures, China Investment and Development (CIDC), Yasuda Enterprise
Development, Partners Healthcare, and GC&H Investments.
The Company has raised $88 million in venture financing to date.
GlobeImmune's lead infectious disease product, GI-5005, is scheduled to
begin a randomized Phase 2 clinical trial in combination with standard of
care in patients with chronic hepatitis C infection at over 40 U.S. centers
in the second half of 2007. The Company's lead oncology product, GI-4000,
is currently being studied in a placebo-controlled Phase 2 clinical trial
in patients with resectable pancreas cancer.
"We are very pleased with the level of investor enthusiasm surrounding our
clinical programs," said Timothy C. Rodell M.D., CEO of GlobeImmune. "The
proceeds from this financing should enable us to reach the primary
endpoints for our lead Phase 2 programs, allow the initiation of two
additional Phase 2 trials for GI-4000, and advance another product into
clinical development."
About GlobeImmune, Inc.
GlobeImmune is a private, Colorado-based company developing active
immunotherapies called Tarmogens® for the treatment of cancer and
infectious diseases. The Company's lead product candidate, GI-5005, is a
Tarmogen being developed for the treatment of chronic hepatitis C infection
that has completed Phase 1b clinical trials. GI-5005 is designed to
complement both the current and emerging standard of care for hepatitis C
infection through the direct elimination of chronically infected cells.
The Company plans to initiate a randomized, placebo-controlled Phase 2
study of GI-5005 in combination with standard of care for chronic hepatitis
C infection before the end of 2007. The Company's lead oncology program,
GI-4000, is designed to be a treatment for cancers of the lung and
gastrointestinal tract. A randomized, placebo-controlled Phase 2 trial in
patients with resectable pancreas cancer in combination with adjuvant
gemcitabine is ongoing.
For additional information, please visit the company's website at
www.globeimmune.com.
This press release contains forward-looking statements that involve risks
and uncertainties, including statements relating to initiation and progress
of the Company's clinical trial programs. Actual results could differ
materially from those projected and the Company cautions readers not to
place undue reliance on the forward-looking statements contained in this
release. This release is for informational purposes only and does not
constitute an offer to sell or the solicitation of an offer to buy any of
the securities nor shall there be any sale of these securities in any state
in which such offer, solicitation or sale would be unlawful prior to
registration or qualification of the securities under the securities laws
of any such state.